CY1117183T1 - Διακλαδισμενα παραγωγα 3-φαινυλοπροπιονικου οξεος και η χρηση τους - Google Patents
Διακλαδισμενα παραγωγα 3-φαινυλοπροπιονικου οξεος και η χρηση τουςInfo
- Publication number
- CY1117183T1 CY1117183T1 CY20161100069T CY161100069T CY1117183T1 CY 1117183 T1 CY1117183 T1 CY 1117183T1 CY 20161100069 T CY20161100069 T CY 20161100069T CY 161100069 T CY161100069 T CY 161100069T CY 1117183 T1 CY1117183 T1 CY 1117183T1
- Authority
- CY
- Cyprus
- Prior art keywords
- branched
- phenylopropionic
- acid products
- treatment
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Abstract
Η παρούσα αίτηση αφορά νέα παράγωγα 3-φαινυλοπροπιονικού οξέος που φέρουν διακλαδισμένους ή κυκλικούς αλκυλοϋποκαταστάτες στη θέση 3, μεθόδους για την παραγωγή τους, τη χρήση τους για τη θεραπευτική αγωγή και/ή πρόληψη παθήσεων καθώς και τη χρήση τους για την παραγωγή φαρμακευτικών μέσων για τη θεραπευτική αγωγή και/ή προφύλαξη παθήσεων, ιδίως για τη θεραπευτική αγωγή και/ή πρόληψη καρδιαγγειακών παθήσεων.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102011007272A DE102011007272A1 (de) | 2011-04-13 | 2011-04-13 | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
EP12711861.0A EP2697191B1 (de) | 2011-04-13 | 2012-03-28 | Verzweigte 3-phenylpropionsäure-derivate und ihre verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1117183T1 true CY1117183T1 (el) | 2017-04-05 |
Family
ID=45928886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100069T CY1117183T1 (el) | 2011-04-13 | 2016-01-26 | Διακλαδισμενα παραγωγα 3-φαινυλοπροπιονικου οξεος και η χρηση τους |
Country Status (42)
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102009012314A1 (de) * | 2009-03-09 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung |
DE102009046115A1 (de) | 2009-10-28 | 2011-09-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 3-Phenylpropansäuren und ihre Verwendung |
BR112013013663A2 (pt) | 2010-12-07 | 2016-09-06 | Bayer Ip Gmbh | ácidos 1-benzilcicloalquilcarboxílicos substituídos e sua utilização |
DE102011007272A1 (de) * | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
WO2013076168A1 (de) | 2011-11-25 | 2013-05-30 | Bayer Pharma Aktiengesellschaft | Verfahren zur herstellung von substituierten 5-fluor-1h-pyrazolopyridinen |
DE102012208530A1 (de) | 2012-05-22 | 2013-11-28 | Bayer Pharma AG | Substituierte Piperidinoacetamide und ihre Verwendung |
MX2015006856A (es) * | 2012-11-30 | 2016-02-17 | Astellas Pharma Inc | Compuestos imidazopiridina. |
WO2014186704A2 (en) * | 2013-05-17 | 2014-11-20 | N30 Pharmaceuticals, Inc. | Novel compounds for the treatment of cystic fibrosis |
US10265314B2 (en) | 2013-07-25 | 2019-04-23 | Bayer Pharma Aktiengesellschaft | SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis |
TW201625584A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
TW201625601A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 噻吩-2-基-吡啶-2-基-1h-吡唑-4-羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
TW201625586A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 環己烯-1-基-吡啶-2-基-1h-吡唑-4-羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
CN107257790A (zh) | 2014-12-18 | 2017-10-17 | 拜耳医药股份有限公司 | 取代的吡啶基‑环烷基‑羧酸、包含它们的组合物及其医学用途 |
KR20180002657A (ko) | 2015-05-06 | 2018-01-08 | 바이엘 파마 악티엔게젤샤프트 | 전신 경화증 (SSc)에 수반되는 수족지 궤양 (DU)의 치료를 위한 sGC 자극제, sGC 활성화제 단독 및 PDE5 억제제와의 조합물의 용도 |
CN113750102A (zh) * | 2015-07-23 | 2021-12-07 | 拜耳制药股份公司 | 可溶性鸟苷酸环化酶的刺激剂和/或活化剂及其用途 |
WO2018069148A1 (de) * | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
WO2018069126A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc stimulatoren und mineralocorticoid-rezeptor-antagonisten |
WO2018153899A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc) |
AU2018354785A1 (en) | 2017-10-24 | 2020-04-23 | Bayer Aktiengesellschaft | Substituted imidazopyridine amides and use thereof |
WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
US11332435B2 (en) | 2017-12-01 | 2022-05-17 | Bayer Pharma Aktiengesellschaft | Method for producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4- chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid and the crystalline form thereof for use as a pharmaceutical ingredient |
EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
EP3787610A1 (en) * | 2018-04-30 | 2021-03-10 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
EA202092680A1 (ru) | 2018-05-15 | 2021-04-13 | Байер Акциенгезельшафт | 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон |
EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
EP3826619A1 (de) | 2018-07-24 | 2021-06-02 | Bayer Aktiengesellschaft | Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung |
MX2021000904A (es) * | 2018-07-24 | 2021-03-31 | Bayer Ag | Forma de dosificacion farmaceutica administrable por via oral con liberacion modificada. |
US10905667B2 (en) * | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
US20220128561A1 (en) | 2019-01-17 | 2022-04-28 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc) |
WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
WO2020216669A1 (de) | 2019-04-23 | 2020-10-29 | Bayer Aktiengesellschaft | Phenylsubstituierte imidazopyridinamide und ihre verwendung |
SG11202111587VA (en) | 2019-05-07 | 2021-11-29 | Bayer Ag | Masp inhibitory compounds and uses thereof |
TW202112359A (zh) | 2019-06-07 | 2021-04-01 | 德商拜耳廠股份有限公司 | sGC活化劑於治療眼科疾病之用途 |
EP3822265A1 (en) | 2019-11-15 | 2021-05-19 | Bayer AG | Substituted hydantoinamides as adamts7 antagonists |
EP3822268A1 (en) | 2019-11-15 | 2021-05-19 | Bayer Aktiengesellschaft | Substituted hydantoinamides as adamts7 antagonists |
EP4011873A1 (en) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
CA3204495A1 (en) | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
WO2022122916A1 (en) | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | Substituted pyrazolyl piperidine carboxylic acids |
EP4011874A1 (en) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
CN115175681A (zh) | 2020-12-10 | 2022-10-11 | 拜耳公司 | sGC活化剂用于治疗眼科疾病的用途 |
EP4339184A1 (en) * | 2021-05-14 | 2024-03-20 | Medshine Discovery Inc. | Alkyl carboxylic acid compounds and application thereof |
WO2023275796A1 (en) * | 2021-07-01 | 2023-01-05 | Novartis Ag | Heterocyclic derivatives as sphingosine-1-phosphate 3 inhibitors |
TW202317510A (zh) * | 2021-07-15 | 2023-05-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 3-苯基丙酸類化合物、其製備方法及其在醫藥上的應用 |
WO2023155873A1 (zh) * | 2022-02-18 | 2023-08-24 | 江苏恒瑞医药股份有限公司 | 羧酸类化合物、其制备方法及其在医药上的应用 |
WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
US4111202A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
NZ206600A (en) | 1983-05-11 | 1987-01-23 | Alza Corp | Osmotic drug delivery device |
ES2039287T3 (es) | 1987-01-14 | 1993-09-16 | Ciba-Geigy Ag | Procedimiento para la obtencion de un sistema terapeutico peroral para productos activos dificilmente solubles. |
US5041453A (en) | 1990-05-30 | 1991-08-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4 |
WO1994012181A1 (en) | 1992-12-01 | 1994-06-09 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
DE4301900A1 (de) | 1993-01-25 | 1994-07-28 | Bayer Ag | 2-Oxochinolin-1-yl-methylphenylessigsäurederivate |
US5643957A (en) * | 1993-04-22 | 1997-07-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
DE4326344A1 (de) | 1993-08-05 | 1995-02-09 | Thomae Gmbh Dr K | Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
FR2722145B1 (fr) | 1994-07-05 | 1996-09-27 | Michelin & Cie | Bande de roulement pour pneumatique hivernaux |
NL9401707A (nl) | 1994-10-17 | 1996-06-03 | Dsm Nv | Werkwijze voor de bereiding van 3-fenylpropaanzuur. |
DE4443892A1 (de) | 1994-12-09 | 1996-06-13 | Bayer Ag | 4-(Chinolin-2-yl-methoxy)-phenyl-essigsäurederivate |
US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
DE19546918A1 (de) | 1995-12-15 | 1997-06-19 | Bayer Ag | Bicyclische Heterocyclen |
EP0802192A1 (de) | 1996-04-17 | 1997-10-22 | Bayer Ag | Heterocyclisch-substituierte Phenylglycinolamide mit antiatherosklerotischer Wirkung und Verfahren zu ihrer Herstellung |
DE19747261A1 (de) | 1997-10-25 | 1999-04-29 | Bayer Ag | Osmotisches Arzneimittelfreisetzungssystem |
DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
WO2000050398A2 (en) | 1999-02-24 | 2000-08-31 | F. Hoffmann-La Roche Ag | Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists |
CZ20013834A3 (cs) | 1999-04-28 | 2002-04-17 | Aventis Pharma Deutschland Gmbh | Deriváty kyselin se třemi arylovými zbytky jako ligandy receptorů PPAR a farmaceutické prostředky, které je obsahují |
EP1177187B1 (en) | 1999-04-28 | 2007-07-25 | Sanofi-Aventis Deutschland GmbH | Di-aryl acid derivatives as ppar receptor ligands |
DE19929065A1 (de) | 1999-06-25 | 2000-12-28 | Bayer Ag | Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
CA2385972A1 (en) | 1999-10-01 | 2001-04-12 | Haruhisa Ogita | Novel diarylamide derivatives and use thereof as medicines |
TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
AU2001258838A1 (en) | 2000-05-29 | 2001-12-11 | Kyorin Pharmaceutical Co. Ltd. | Substituted phenylpropionic acid derivatives |
JP4929472B2 (ja) | 2000-08-22 | 2012-05-09 | 小野薬品工業株式会社 | カルボン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 |
AU2001288067A1 (en) | 2000-09-21 | 2002-04-02 | Sankyo Company Limited | Phenylpropionic acid derivatives |
EP1330432A2 (en) | 2000-11-04 | 2003-07-30 | Aventis Pharma Limited | Substituted alkanoic acids |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
JPWO2002046161A1 (ja) | 2000-12-05 | 2004-04-08 | 杏林製薬株式会社 | 置換カルボン酸誘導体 |
CA2433573A1 (en) | 2000-12-28 | 2002-07-11 | Takeda Chemical Industries, Ltd. | Alkanoic acid derivatives, process for their production and use thereof |
EP1394154A4 (en) | 2001-03-23 | 2005-05-18 | Takeda Pharmaceutical | HETEROCYCLIC DERIVATIVE WITH FIVE MEMBERS OF ALKANOIC ACID |
US7244861B2 (en) | 2001-03-30 | 2007-07-17 | Eisai Co., Ltd. | Benzene compound and salt thereof |
US20030105097A1 (en) | 2001-05-14 | 2003-06-05 | Pfizer Inc. | Alkylamide compounds |
MXPA04001253A (es) | 2001-08-09 | 2004-06-03 | Ono Pharmaceutical Co | Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo. |
WO2003016265A1 (fr) | 2001-08-17 | 2003-02-27 | Eisai Co., Ltd. | Compose cyclique et agoniste du recepteur ppar |
US20030161882A1 (en) | 2002-02-01 | 2003-08-28 | Waterman Kenneth C. | Osmotic delivery system |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
WO2004024705A1 (ja) | 2002-09-10 | 2004-03-25 | Takeda Pharmaceutical Company Limited | 5員複素環化合物 |
US20050187266A1 (en) | 2003-04-15 | 2005-08-25 | Pfizer Inc | Alpha substituted carboxylic acids |
US20050234066A1 (en) | 2004-04-15 | 2005-10-20 | Agouron Pharmaceuticals, Inc. | Alpha substituted carboxylic acids |
CN1812978A (zh) | 2003-04-30 | 2006-08-02 | 药物研发有限责任公司 | 作为蛋白酪氨酸磷酸酶-1b抑制剂的苯基取代羧酸 |
BRPI0508098A (pt) | 2004-02-27 | 2007-07-17 | Amgen Inc | compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos |
EP1786821B1 (en) | 2004-07-19 | 2009-09-16 | Intercasting Corporation | Dynamic knowledge-based networking system and method |
EP1801698A1 (en) | 2004-08-10 | 2007-06-27 | Microelectronica Española, S.A. | Processing unit and method of managing storage in processing systems with limited resources |
MY145712A (en) * | 2004-09-15 | 2012-03-30 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
WO2006050097A1 (en) | 2004-10-28 | 2006-05-11 | The Institutes For Pharmaceutical Discovery, Llc | Substituted phenylalkanoic acids |
CA2587566A1 (en) | 2004-11-18 | 2006-05-26 | The Institutes For Pharmaceutical Discovery, Llc | Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors |
GT200500375A (es) | 2004-12-20 | 2006-11-28 | Derivados de piperidina y su uso como agentes antiinflamatorios | |
DE102004062475A1 (de) | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
PL372356A1 (pl) | 2005-01-20 | 2006-07-24 | ADAMED Sp.z o.o. | Nowe związki, pochodne kwasu 3-fenylopropionowego |
EP1939189A4 (en) | 2005-08-26 | 2013-03-13 | Shionogi & Co | DERIVATIVE HAVING AGONIST ACTIVITY AGAINST PPAR |
DE102005050377A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Heterocyclische Verbindungen und ihre Verwendung |
CN101116660A (zh) * | 2006-08-04 | 2008-02-06 | 瑟维尔实验室 | 抗动脉粥样化血栓形成的化合物在获得用于治疗血管疾病的药物中的用途 |
WO2009067493A2 (en) | 2007-11-19 | 2009-05-28 | Envivo Pharmaceuticals, Inc. | 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders |
DE102008018675A1 (de) | 2008-04-14 | 2009-10-15 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclisch substituierte Carbonsäure-Derivate und ihre Verwendung |
SG192439A1 (en) | 2008-06-27 | 2013-08-30 | Novartis Ag | Organic compounds |
EP2179993A1 (de) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoxidsubstituierte Anilinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
EP2179992A1 (de) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
DE102008059206A1 (de) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
DE102009012314A1 (de) | 2009-03-09 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung |
DE102009046115A1 (de) * | 2009-10-28 | 2011-09-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 3-Phenylpropansäuren und ihre Verwendung |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
MX2013000198A (es) | 2010-07-09 | 2013-01-28 | Bayer Ip Gmbh | Pirimidinadas y triazinas condensadas y su uso. |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
BR112013013663A2 (pt) | 2010-12-07 | 2016-09-06 | Bayer Ip Gmbh | ácidos 1-benzilcicloalquilcarboxílicos substituídos e sua utilização |
DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
DE102012208530A1 (de) | 2012-05-22 | 2013-11-28 | Bayer Pharma AG | Substituierte Piperidinoacetamide und ihre Verwendung |
PT2875003T (pt) | 2012-07-20 | 2017-02-16 | Bayer Pharma AG | Novos ácidos 5-amino-tetra-hidroquinolina-2-carboxílicos e sua utilização |
WO2018069148A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
US11332435B2 (en) | 2017-12-01 | 2022-05-17 | Bayer Pharma Aktiengesellschaft | Method for producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4- chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid and the crystalline form thereof for use as a pharmaceutical ingredient |
EP3826619A1 (de) | 2018-07-24 | 2021-06-02 | Bayer Aktiengesellschaft | Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung |
US20200237648A1 (en) | 2018-07-24 | 2020-07-30 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-released pharmaceutical dosage form |
US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
TW202112359A (zh) | 2019-06-07 | 2021-04-01 | 德商拜耳廠股份有限公司 | sGC活化劑於治療眼科疾病之用途 |
-
2011
- 2011-04-13 DE DE102011007272A patent/DE102011007272A1/de not_active Withdrawn
-
2012
- 2012-03-26 TW TW101110304A patent/TWI549933B/zh active
- 2012-03-26 UY UY0001033970A patent/UY33970A/es active IP Right Grant
- 2012-03-27 AR ARP120101024A patent/AR085586A1/es active IP Right Grant
- 2012-03-27 US US13/431,934 patent/US8796335B2/en active Active
- 2012-03-27 JO JOP/2012/0066A patent/JO3091B1/ar active
- 2012-03-28 CU CUP2013000137A patent/CU24183B1/es active IP Right Grant
- 2012-03-28 ES ES12711861.0T patent/ES2561753T3/es active Active
- 2012-03-28 PT PT127118610T patent/PT2697191E/pt unknown
- 2012-03-28 JP JP2014504240A patent/JP5911950B2/ja active Active
- 2012-03-28 AU AU2012242122A patent/AU2012242122B2/en active Active
- 2012-03-28 KR KR1020137029773A patent/KR101944559B1/ko active IP Right Grant
- 2012-03-28 RS RS20160043A patent/RS54527B1/en unknown
- 2012-03-28 ME MEP-2016-12A patent/ME02310B/me unknown
- 2012-03-28 SG SG10201602852WA patent/SG10201602852WA/en unknown
- 2012-03-28 BR BR112013026466-7A patent/BR112013026466B1/pt active IP Right Grant
- 2012-03-28 WO PCT/EP2012/055474 patent/WO2012139888A1/de active Application Filing
- 2012-03-28 MY MYPI2013701912A patent/MY173877A/en unknown
- 2012-03-28 EA EA201301154A patent/EA023990B1/ru not_active IP Right Cessation
- 2012-03-28 CN CN201280028866.2A patent/CN103796989B/zh active Active
- 2012-03-28 PE PE2013002244A patent/PE20140630A1/es active IP Right Grant
- 2012-03-28 UA UAA201313123A patent/UA110054C2/ru unknown
- 2012-03-28 MA MA36326A patent/MA35039B1/fr unknown
- 2012-03-28 CA CA2832970A patent/CA2832970C/en active Active
- 2012-03-28 DK DK12711861.0T patent/DK2697191T3/en active
- 2012-03-28 SI SI201230442T patent/SI2697191T1/sl unknown
- 2012-03-28 SG SG2013071758A patent/SG193941A1/en unknown
- 2012-03-28 AP AP2013007164A patent/AP3482A/xx active
- 2012-03-28 EP EP12711861.0A patent/EP2697191B1/de active Active
- 2012-03-28 MX MX2013011774A patent/MX337712B/es active IP Right Grant
- 2012-03-28 PL PL12711861T patent/PL2697191T3/pl unknown
- 2012-03-28 HU HUE12711861A patent/HUE026859T2/en unknown
-
2013
- 2013-10-02 IL IL228677A patent/IL228677A/en active IP Right Grant
- 2013-10-10 CR CR20130524A patent/CR20130524A/es unknown
- 2013-10-10 EC EC2013012966A patent/ECSP13012966A/es unknown
- 2013-10-10 TN TNP2013000411A patent/TN2013000411A1/fr unknown
- 2013-10-10 CL CL2013002902A patent/CL2013002902A1/es unknown
- 2013-10-10 CO CO13241304A patent/CO6801742A2/es active IP Right Grant
- 2013-10-11 DO DO2013000239A patent/DOP2013000239A/es unknown
- 2013-10-11 GT GT201300243A patent/GT201300243A/es unknown
- 2013-11-12 ZA ZA2013/08490A patent/ZA201308490B/en unknown
-
2014
- 2014-06-13 US US14/304,171 patent/US20140309307A1/en not_active Abandoned
-
2016
- 2016-01-26 CY CY20161100069T patent/CY1117183T1/el unknown
- 2016-01-28 HR HRP20160100TT patent/HRP20160100T1/hr unknown
- 2016-05-18 US US15/158,331 patent/US10023528B2/en active Active
-
2018
- 2018-06-06 US US16/001,146 patent/US10259776B2/en active Active
- 2018-12-21 US US16/230,957 patent/US20190185415A1/en not_active Abandoned
-
2020
- 2020-06-18 US US16/904,786 patent/US11377417B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1117183T1 (el) | Διακλαδισμενα παραγωγα 3-φαινυλοπροπιονικου οξεος και η χρηση τους | |
CY1118588T1 (el) | Νεα 5-αμινοτετραϋδροκινολινο-2-καρβοξυλικα οξεα και η χρηση τους | |
CY1120832T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
CY1119123T1 (el) | Δις-αρυλοσυζευγμενες αρυλοτριαζολονες και η χρηση τους | |
CY1117372T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους | |
CY1121150T1 (el) | Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας | |
UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
CY1117123T1 (el) | Παραγωγα οιστρα-1,3,5(10),16-τετραενο-3- καρβοξαμιδιου, μεθοδοι για την παραγωγη αυτων, φαρμακευτικα παρασκευασματα που τα περιεχουν καθως και η χρηση αυτων για την παραγωγη φαρμακευτικων μεσων | |
CY1116791T1 (el) | 4-αρυλ-ν-φαινυλ-1,3,5-τριαζιν-αμινες που περιεχουν μια ομαδα σουλφοξιμινης | |
ECSP13012668A (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
NZ629996A (en) | 2’- substituted carba-nucleoside analogs for antiviral treatment | |
CY1115403T1 (el) | Αλκυλαμινο-υποκατεστημενες δικυανοπυριδινες και προφαρμακα τυπου εστερα αμινοξεος αυτων | |
DK3045456T3 (da) | Bicyklisk substituerede uraciler og anvendelse heraf | |
BR112014012407A2 (pt) | amidas de piridona e análogos exibindo propriedades anti-câncer e anti-proliferativas | |
MX2018003569A (es) | Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos. | |
EA201792071A2 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
DOP2016000276A (es) | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS | |
CY1115590T1 (el) | Σουλφοξιμινυποκατεστημενα παραγωγα ανιλινοπυριμιδινης ως cdk-αναστολεις, η παραγωγη αυτων και η χρηση αυτων ως φαρμακευτικα μεσα | |
PH12015500585A1 (en) | Modified hyaluronic acid derivatives and use thereof | |
EA201591704A1 (ru) | Новые устойчивые соли пентадекапептида, способ их получения, их применение в производстве фармацевтических составов и их применение в терапии | |
TR201905218T4 (tr) | Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler. | |
EA201400786A1 (ru) | Карбоциклические нуклеозиды, их фармацевтическое применение и композиции | |
PL410369A1 (pl) | Nowe pochodne peptydowe, sposób ich otrzymywania, kompozycja farmaceutyczna, kompozycja dezynfekująca oraz zastosowanie i zestaw | |
UA113887C2 (xx) | 5-амінотетрагідрохінолін-2-карбонові кислоти і їх застосування |